Comorbid pathology in patients with hyperuricemia in the Khabarovsk region

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: Uric acid can affect many metabolic processes in the human body. In recent decades, great importance has been given to increased levels of uric acid — hyperuricemia. Hyperuricemia has been proven to be an independent risk factor for the development of cardiovascular, renal and metabolic diseases, and not just their marker, as had previously ben considered.

AIM: To determine the incidence of hyperuricemia at the primary outpatient stage, as well as to assess the prevalence of comorbid pathology among patients with hyperuricemia in the Khabarovsk Territory.

MATERIALS AND METHODS: We analyzed 5261 medical records of the patients who applied for an initial outpatient appointment at the Clinical Diagnostic Center and the Viveya Consultative and Diagnostic Center in Khabarovsk from November 2022 to November 2023. From the total number of medical records 2428 patients had elevated level of uric acid in the blood.

RESULTS: Arterial hypertension (60.5%) was the most common pathology; obesity – the second (27.35%); diabetes mellitus type 2 was less common in the patients with hyperuricemia (17.75%), and nephrolithiasis was the least common pathology (7.91%).

CONCLUSIONS: A high prevalence of hyperuricemia among the population of the Khabarovsk Territory was revealed. Elevated levels of uric acid affect the development of comorbid pathology in the patients, in particular cardiovascular pathology. The results obtained during the study indicate a high prevalence of comorbid diseases in hyperuricemia with arterial hypertension being the most frequent.

作者简介

Elvira Otteva

Institute for Advanced Training of Healthcare Specialists

编辑信件的主要联系方式.
Email: elvott@mail.ru
ORCID iD: 0000-0002-2365-5734
SPIN 代码: 6218-8262

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 9 Krasnodarskaya St., Khabarovsk, 680009

Polina Pyatnitskaya

Institute for Advanced Training of Healthcare Specialists

Email: strizhik-38@mail.ru
ORCID iD: 0000-0002-6732-1146
SPIN 代码: 8778-2472

postgraduate student

俄罗斯联邦, 9 Krasnodarskaya St., Khabarovsk, 680009

Larisa Khoruk

Consultative and Diagnostic Center “Viveya”

Email: Khoruk_larisa@mail.ru
ORCID iD: 0009-0003-4754-7142
SPIN 代码: 6468-9145

MD

俄罗斯联邦, Khabarovsk

Tatiana Kocherova

Consultative and Diagnostic Center “Viveya”

Email: tanka55@inbox.ru
ORCID iD: 0000-0002-0625-7507
SPIN 代码: 5654-0699

MD, Dr. Sci. (Med.)

俄罗斯联邦, Khabarovsk

参考

  1. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–1741. doi: 10.1097/HJH.0000000000000701
  2. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–1190. doi: 10.1161/01.HYP.0000069700.62727.C5
  3. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on the management of patients with hyperuricemia and high cardiovascular risk: 2022. Systemic hypertension. 2022;19(1):5–22. EDN: HBLVVV doi: 10.38109/2075-082X-2022-1-5-22
  4. Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. EDN: SCOUHN doi: 10.20996/1819-6446-2014-10-2-153-159
  5. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1246. doi: 10.1093/rheumatology/kex250
  6. Borghi C, Domienik-Karlowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14. doi: 10.5603/CJ.a2021.0001
  7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. doi: 10.1097/HJH.0000000000001940
  8. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. EDN: TCRBRB doi: 10.15829/1560-4071-2020-3-3786
  9. Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237–247. doi: 10.1111/j.1523-1755.2005.00074.x
  10. Mazurov VI, Drapkina OM, Martynov AI, et al. Meta-analysis of observational cohort studies on the association of asymptomatic hyperuricemia with chronic kidney disease. Therapy. 2023;9(10):21–39. doi: 10.18565/therapy.2023.10.21-39
  11. Nasonova VA, Barskova VG. Early diagnostic and treatment of gout — is scientifically based reguirements for improvement of labour and living prognosis of patients. Rheumatology Science and Practice. 2004;42(1):5–7. EDN: QCWYZP doi: 10.14412/1995-4484-2004-1374
  12. Chen-Xu M, Yokose C, Rai S.K, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. doi: 10.1002/art.40807
  13. Kumar AUA, Browne LD, Li X, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006–2014: A cohort study. PLoS One. 2018;13(5):e0198197. doi: 10.1371/journal.pone.0198197
  14. Sumpter NA, Saag KG, Reynolds RJ, Merriman TR. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126–133. doi: 10.1097/BOR.0000000000000691
  15. Sandoval-Plata G, Nakafero G, Chakravorty M, et al. Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank. Rheumatology (Oxford). 2021;60(7):3243–3251. doi: 10.1093/rheumatology/keaa773
  16. Mazurov VI, Sayganov SA, Bashkinov RA, et al. The effect of urate-lowering therapy on the course of chronic kidney disease in patients with osteoarthritis and asymptomatic hyperuricemia. Therapy. 2023;9(7):56–71. doi: 10.18565/therapy.2023.7.56-71
  17. Mazurov VI, Sayganov SA, Martynov AI, et al. Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials. Herald of North-Western State Medical University named after I.I. Mechnikov. 2023;15(4):5–18. EDN: ESRPKU doi: 10.17816/mechnikov604850
  18. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283–289. doi: 10.1002/art.20761
  19. Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15(1):122. doi: 10.1186/1471-2369-15-122
  20. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):S11–S16. doi: 10.1016/j.semarthrit.2020.04.008
  21. Mazurov VI, Petrova MS, Gaidukova IZ, et al. Features of gouty arthritis according to the St. Petersburg City Gout Registry 2016–2018. Therapy. 2019;6(32):27–34. doi: 10.18565/therapy.2019.6.27-34
  22. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–3141. doi: 10.1002/art.30520
  23. Mazurov VI, Gaidukova IZ, Bashkinov RA, et al. Asymptomatic hyperuricemia impact on the comorbid pathology course in patients with osteoarthritis and the possibility of its correction. RMJ. 2021;29(6):56–62. EDN: GDWNGZ
  24. Mazurov VI, Bashkinov RA, Fonturenko AYu, et al. Features of the course of rheumatoid arthritis and osteoarthritis in patients with asymptomatic hyperuricemia. Herald of North-Western State Medical University named after I.I. Mechnikov. 2020;12(3):63–72. EDN: XQZWVY doi: 10.17816/mechnikov44234
  25. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–252. doi: 10.1161/01.HYP.0000085858.66548.59
  26. Yarovoy SK, Maksudov RR. Purine metabolism disturbances in the urological practice. Experimental and clinical urology. 2013;(3):88–93. EDN: REDDLV
  27. Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207. doi: 10.1186/s12872-016-0379-z
  28. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam Study. Stroke. 2006;37(6):1503–1507. doi: 10.1161/01.STR.0000221716.55088.d4
  29. Drapkina OM, Mazurov VI, Martynov AI, et al. “Focus on hyperuricemia.” Resolution of the expert council. Cardiovascular therapy and prevention. 2023;22(4):77–84. EDN: KRCKAU doi: 10.15829/1728-8800-2023-3564
  30. Chazova IE, Zhernakova JuV, Kisliak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019;16(4):8–21. EDN: HSKPCZ doi: 10.26442/2075082X.2019.4.190686
  31. Zhilyaev EV. Changes in strategies for gout treatment. Difficult patient. 2017;15(10–11):1–19.

版权所有 © Eco-Vector, 2024



##common.cookie##